Aurobindo Aims $2 Billion Revenue, Eyes Foreign Markets

Hyderabad-based Aurobindo Pharma aims to achieve a revenue of $2 billion (Rs 12,000 crore) in FY2014-15. It is also eyeing European, Australian and Japanese markets.

In its annual report for FY2013-14, the company said, "Leveraging on its large state-of-the-art manufacturing infrastructure for APIs and formulations, wide and diversified basket of products and confidence of its customers, the company aims to achieve $2 billion revenues by 2014-15." It earned a revenue of Rs 8,099.79 crore in the last financial year.

The report said efforts were afoot to strengthen business presence in Japan, Brazil, South Africa, Canada, Australia, North and West Africa and West Asia. "These initiatives would also help consolidate Aurobindo's volumes and revenues over the long term, thereby spreading the risk portfolio."

The company is making progress in developing anti-cancer drugs and hormonal products. "In 2014-15, filings for approvals are being planned for a few products," the company said in the report.

"In the injectable business, going forward, we are gearing ourselves for a meaningful growth in the medium term. We have 45 files with FDA under review, and we hope to file nine more in 2014-15 and another 30 in 2015-16," said Arvind Vasudeva, CEO – formulations, Aurobindo Pharma.